| OPUS GENETICS DL-,0001 |
| USA |
| Gesundheit |
| US67577R1023 / A2QG4Z |
| R3X1 (Frankfurt) |
| FRA:R3X1, ETR:R3X1, R3X1:GR |
| - |
| https://opusgtx.com/ |
|
Opus Genetics Inc. is a biotechnology company focusing on developing innovative gene therapies for inherited retinal diseases. Their primary mission is to address unmet medical needs for patients suffering from these rare genetic conditions that ofte..
>Volltext.. |
| 289.08 Mio. EUR |
| 251.67 Mio. EUR |
| 12.3 Mio. EUR |
| -33.39 Mio. EUR |
| -42.96 Mio. EUR |
| -0.73 EUR |
| 0.98 Mio. EUR |
| 39.06 Mio. EUR |
| -30.54 Mio. EUR |
| 5.8 |
| 13.83% |
| 24.03% |
| - |
| - |
| - |
| - |
| OPUS GENETICS |
| 04.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|